Attorney Docket No. 0470-052056

## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims**

Claims 1-20 (cancelled)

Claim 21 (new): A method of preventing malnutrition as a result of insufficient food ingestion in a mammal in need thereof, said method comprising orally administering a lactoferrin-containing nutritional composition in an amount effective to reduce the residence time of nutrients in the stomach of the mammal, said lactoferrin-containing composition exhibiting a weight ratio of lactoferrin to  $\beta$ -lactoglobulin that exceeds 1 to 15 and containing 0.1-20 wt.% lipids,  $\omega$ -3-fatty acids (including  $\omega$ -3-fatty acid residues) representing at least 5 wt.% of the total amount of lipids.

Claim 22 (new): The method according to claim 21, wherein the lactoferrin-containing nutritional composition contains at least 0.2 wt.% lactoferrin.

Claim 23 (new): The method according to claim 21, wherein the lactoferrin-containing nutritional composition contains at least 0.05 wt.% lactoferrin and 0-0.15 wt.% glycomacropeptide.

Claim 24 (new): The method according to claim 21, wherein lactoferrin is administered in a dosage of at least 0.1 g.

Claim 25 (new): The method according to claim 21, wherein a pourable nutritional composition having a caloric content of at least 1 kcal/ml and a viscosity of 100 mPa.s or less at 21°C is administered.

Application No. Not Yet Assigned Paper Dated: July 6, 2005 In Reply to USPTO Correspondence of N/A

Attorney Docket No. 0470-052056

Claim 26 (new): The method according to claim 21, further comprising co-administering a carnitine source in an amount equivalent to at least 10 mg L-carnitine.

Claim 27 (new): The method according to claim 21, wherein the lactoferrin-containing nutritional composition is administered in an amount of 20-400 ml.

Claim 28 (new): The method according to claim 21, wherein the mammal is hospitalized patient or suffers from impaired gastric motility.

Claim 29 (new): The method according to claim 21, wherein the mammal is a patient undergoing chemotherapy.

Claim 30 (new): The method according to claim 21, wherein the lactoferrin-containing nutritional composition is consumed within 1 hour prior to or during physical exercise.

Claim 31 (new): A pourable artificial nutritional composition having a caloric content of at least 1.0 kcal/ml and a viscosity of 100 mPa.s or less at 21°C, comprising:

- a) 50-79.6 wt.% water;
- b) at least 0.4 wt.% lactoferrin;
- c) 1-30 wt.% proteinaceous matter other than lactoferrin;
- d) 0.1-20 wt.% lipids; and
- e) 10-30 wt.% carbohydrates;

wherein the combination of these components constitutes at least 80 wt.% of the composition, and the proteinaceous matter, lipids and/or carbohydrates together constitute at least 20 wt.% of the composition.

Claim 32 (new): The nutritional composition according to claim 31, wherein the weight ratio of lactoferrin to  $\beta$ -lactoglobulin exceeds 1 to 15.

Application No. Not Yet Assigned Paper Dated: July 6, 2005 In Reply to USPTO Correspondence of N/A Attorney Docket No. 0470-052056

Claim 33 (new): The nutritional composition according to claim 31, wherein not more than 10 wt.% of the proteinaceous matter is hydrolyzed protein.

Claim 34 (new): The nutritional composition according to claim 31, wherein the lipids and the carbohydrates together constitute at least 13 wt.% of the composition.

Claim 35 (new): The nutritional composition according to claim 31, wherein the nutritional composition contains at least 5 wt.%  $\omega$ -3-fatty acids (including  $\omega$ -3-fatty acid residues) by weight of the total amount of lipids.

Claim 36 (new): The nutritional composition according to claim 31, wherein the nutritional composition contains  $\omega$ -6-fatty acid residues and  $\omega$ -3-fatty acid residues in a weight ratio between 6:1 and 1:3.

Claim 37 (new): The nutritional composition according to claim 31, wherein the nutritional composition contains at least 5 wt.%  $C_8$ - $C_{14}$  fatty acids (including  $C_8$ - $C_{14}$  fatty acid residues) by weight of the total amount of fatty acids.

Claim 38 (new): The nutritional composition according to claim 31, wherein the nutritional composition contains at least 10 wt.% of carbohydrates with a glycemic index of less than 80.

Claim 39 (new): The nutritional composition according to claim 31, wherein the nutritional composition contains at least 0.015 wt.% carnitine.

Claim 40 (new): A packaged artificial nutritional product comprising 20-400 ml of a nutritional composition according to claim 31.